Breast Neoplasms  >>  Perjeta (pertuzumab)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Perjeta (pertuzumab) / Roche
MINT, NCT01501487: I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

Completed
4
226
US
TAC chemotherapy, TC chemotherapy, Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy, TCH chemotherapy, T + trastuzumab followed by CEF + trastuzumab, Dose dense AC followed by T + trastuzumab, Dose dense AC followed by T + trastuzumab + pertuzumab, PTH followed by dose dense AC of FEC
Agendia, University of South Florida, University of Miami, Morton Plant Mease Health Care, AdventHealth, Plano Cancer Center, Ohio State University Comprehensive Cancer Center, University of Oklahoma, University of South Alabama
Breast Cancer
02/16
06/17

Download Options